Tezepelumab Reduces Mucus Plugs in Adults With Uncontrolled Asthma
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 29, 2023 -- Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of NEJM Evidence.
Lars H. Nordenmark, Ph.D., from AstraZeneca in Oslo, Norway, and colleagues assessed the anti-inflammatory effect of tezepelumab in participants of the CASCADE trial, in which patients (aged 18 to 75 years old) with moderate-to-severe, uncontrolled asthma were randomly assigned (1:1) to 210 mg tezepelumab (37 patients) or placebo (45 patients) every four weeks subcutaneously for at least 28 weeks.
The researchers found that the absolute change from baseline in mean mucus plug score was −1.7 in patients receiving tezepelumab and 0.0 in patients receiving placebo. There was a positive correlation observed at baseline between mucus plug scores and levels of inflammatory biomarkers (blood eosinophils, eosinophil-derived neurotoxin, fractional exhaled nitric oxide, interleukin-5, and interleukin-13), as well as a negative association with lung function measures (prebronchodilator forced expiratory volume in 1 second and forced mid-expiratory flow). Reductions in mucus plug scores for patients receiving tezepelumab were correlated with improvements in lung function and reductions in blood eosinophil count and levels of eosinophil-derived neurotoxin, a biomarker of eosinophilic degranulation.
"The reduction in occlusive mucus plugs in these patients is consistent with the idea that reducing mucus plugs is a component of the salutary therapeutic effect of tezepelumab," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Amgen, which manufacture tezepelumab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
FDA Adds Fasenra Indication for Severe Asthma in Children
TUESDAY, April 16, 2024 -- The U.S. Food and Drug Administration has approved an additional indication for Fasenra (benralizumab) as an add-on maintenance treatment for patients...
SARS-CoV-2 Positivity Not Linked to New Asthma Diagnosis in Children
FRIDAY, April 12, 2024 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) positivity in children is not associated with an increased...
Widening of Disparities in Pollution-Attributed Health Burden Observed
THURSDAY, March 14, 2024 -- There has been a widening of racial and ethnic relative disparities in the pollution-attributable health burden within the United States, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.